![Page 1: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/1.jpg)
PERSONALIZED MEDICINE
JAMES WEIS AND LILY CHAN
![Page 2: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/2.jpg)
Personalized medicine takes into account individual genetic differences
Traditionally, doctors used: Family history Socioeconomic circumstances Environmental factors
Now: genomic/genetic testing proteomic profiling metabolomic analysis (study metabolites)
![Page 3: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/3.jpg)
Effectiveness of drugs:
![Page 4: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/4.jpg)
Danger of drugs:
6.7% of patients in hospitals experience serious drug reactions
![Page 5: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/5.jpg)
Old Paradigm:
![Page 6: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/6.jpg)
New Paradigm:
![Page 7: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/7.jpg)
Future Paradigm:
![Page 8: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/8.jpg)
Personalized Medicine Today
![Page 9: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/9.jpg)
The Plan
![Page 10: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/10.jpg)
The Plan:
![Page 11: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/11.jpg)
The Plan:
![Page 12: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/12.jpg)
IT/CS Challenges
Medical Challenges
Biological Challenges
Engineering Challenges
![Page 13: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/13.jpg)
P.M.
![Page 14: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/14.jpg)
(WHEW)
Breather…
![Page 15: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/15.jpg)
Gene Sequencing / Testing
RFLP analysisSNPs (single nucleotide polymorphisms)
More than 1.4 million SNPs were identified in the initial sequencing of the human genome, with over 60,000 of them in the coding region of genes (Evans and McLeod 2003). (but even silent mutations can affect phenotype)
![Page 16: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/16.jpg)
The accuracy of DTC genome-scan tests has been questioned, but Venter et al. found that the genotypes, or particular DNA bases observed, of an individual’s markers from 23andMe and Navigenics agreed more than 99.7% of the time. Same for most other tests.
![Page 17: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/17.jpg)
Do predicted disease risks have any clinical validity? Genotype-phenotype correlation?
Certain disease risks can be better predicted than others.
What the tests do disagree on, however, is the disease risk…
![Page 18: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/18.jpg)
DOES ONE SIZE REALLY FIT ALL?
Pharmacogenomics
![Page 19: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/19.jpg)
Pharmacogenetics
Study of genetic variation that gives rise to different responses to drugs
It is estimated that genetics can account for 20 to 95 percent of variability in drug disposition and effects.
Nongenetic factors include: age, organ function, concomitant therapy, drug interactions, and the nature of the disease.
![Page 20: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/20.jpg)
Pharmacogenomics – Under the PM Umbrella
Better medication choices 100,000 Americans die annually and 2,000,000+ are
hospitalized due to adverse reactions to medications Predict individual reactions to dugs
Safer dosing options More exact dosing, optimum result/side effect balance
Improvements in drug development Exclude genetic variations from certain clinical trials,
speeding up drug design time
![Page 21: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/21.jpg)
Polygenic Determinants of Drug Response
Nine possible combinations of drug-metabolism and drug-receptor genotypes and the corresponding drug-response phenotypes. Each yields a different therapeutic index (efficacy:toxicity ratios) ranging from 13 (65 percent:5 percent) to 0.125 (10 percent:80 percent).
Differences in drug sensitivity and renal clearance
http://content.nejm.org/cgi/content/full/348/6/538
![Page 22: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/22.jpg)
Proteomic Profiling
Relevant in the identification and predisposition to disease
Josh’s presentation
![Page 23: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/23.jpg)
Metabolomic Analysis
First from urine analysisNetworks of metabolite feedback pathways regulate
gene and protein expression. Metabolites also can mediate signaling between organisms.
Biomarkers of disease (diagnostics)The metabolome is therefore most predictive of
phenotype (Fiehn 2002; Weckwerth 2003).However, “…an understanding of the resulting data is
limited owing to a fundamental lack of biochemical and physiological knowledge about network organization…”
![Page 24: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/24.jpg)
Metabolite target analysis
Metabolic profiling
Metabolomics Metabolite fingerprinting
all metabolites, present in a cell or sample. Comprehensiveanalysis of entire metabolome under a given set of conditions.
the intention is not to identify each observed compound but tocompare patterns or fingerprints ofmetabolites that change in response to disease or toxin exposure. Use statistical tools to look for major differences.
focus on one specific metabolite
group of metabolites, i.e those associated with a specific pathway.Extraction method (capillary electrophoresis, gas or liquid chromatography) specially designed for compounds in class to eliminateunwanted/ irrelevant metabolites.
http://swift.cmbi.ru.nl/euroschool/meta_seminar1.pdf
Metabolomic Analysis
![Page 25: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/25.jpg)
static dynamic
![Page 26: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/26.jpg)
SOME BRIEF CASE STUDIES
Applications of Personalized Medicine
![Page 27: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/27.jpg)
Cytochrome P450 genotyping test Enzyme group ‘cytochrome P450’ (CYP450 Many types of medications(including antidepressents,
anticoagulants, proton pump inhibitors, etc) Determine dosing and effects of these drugs.
Thiopurine methyltransferase test Thiopurine Thiopurine methyltransferase (TPMT)
UGT1A1 TA repeat genotype test Irinotecan (Camptosar) UGT1A1 enzyme
Dihydropyrimidine dehydrogenase test 5-flourouracil (5-FU) Dihydropyrimidine dehydrogenase enzyme Responsible for breaking down 5-FU
![Page 28: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/28.jpg)
Uses in Muscular Dystrophy:
Becker and Duchenne MD – same family of disease; Duchenne’s more severe than Becker’s because generally the reading frame is preserved in BMD while it is not in DMD.
DMD – death around age 20; BMD – life expectancy may be reduced, but some have a normal life span. Severity partially depends on mutation.
Dystrophin is the largest known gene in the human body, located on the X chromosome.
79 exons~15% caused by premature
stop codonsPhenotype-genotype
correlation studies
![Page 29: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/29.jpg)
Gentamicin treatment in DMD/BMD
Aminoglycoside antibiotic synthesized by MicromonosporaWorks by binding the 30S subunit (inhibition site) of the bacterial
ribosome, interrupting protein synthesis (stop codon readthrough)
Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. (Wagner et al 2001)
Some success in mdx mouse model – suppressed truncation of protein and improved phenotype.
Cons: highly nephrotoxic; can have psychiatric side effects.
![Page 30: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/30.jpg)
Ataluren (PTC-124) and PRO051
Mutation specificBoth aim to restore reading frame:
Ataluren does this through ribosomal stop codon readthrough PRO051 does this through exon skipping (block splicing machinery)
Duchenne Becker phenotype
![Page 31: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/31.jpg)
•Nonsense mutations result in a premature stop codon (UAG, UAA, or UGA) and cause a truncated protein.
•Works best on UGA stop codon.
Concept applicable to other diseases that also result from nonsense mutations, such as cystic fibrosis and nonsense-mutation hemophilia A and B (nmHA/B).
Ataluren mechanism
![Page 32: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/32.jpg)
As mentioned before, only ~15% have nonsense mutations. Others have deletions, inversions, insertions, point mutations that do not result in a stop codon…
Many specific sequences will be required for effectively treating the majority of patients with DMD. Will each specific sequence need to go through full testing required by the Food and Drug Administration (FDA)?
Toxicity standards?
![Page 33: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/33.jpg)
Analysis of Dystrophin Deletion Mutations Predicts Age of Cardiomyopathy Onset in Becker Muscular Dystrophy
![Page 34: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/34.jpg)
Irinotecan
Treatment for cancer that works by inhibiting topoisomerase 1, which prevents DNA from unwinding.
Clinical studies have revealed significant associations between UGT1A1*28 and irinotecan toxicity.
A recommended strategy for irinotecan-dose adjustments based on individual genetic factors has not yet been fully established.
![Page 35: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/35.jpg)
Selzentry™ (Pfizer)
CCR5-tropic HIV treatment (CD4 immune cells)
Ineffective for CXCR4-tropic strains of HIVTrofile ™ assay to determine patients strain
of HIV Detect virus that does not act through CCR5 at levels
as low as 0.3% of a viral population
Clinical trial patients selected with Trofile ™ assay
![Page 36: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/36.jpg)
“The Food and Drug Administration, in a
harbinger of likely future actions, has just approved a drug-diagnostic combination for AIDS patients who are running out of treatment options … the hallmark of
personalized medicine.”Edward Abrahams
Personalized Medicine Coalition, 2007
![Page 37: Personalized Medicine James Weis and Lily Chan](https://reader036.vdocuments.site/reader036/viewer/2022062518/56814871550346895db57b9e/html5/thumbnails/37.jpg)
OR IS IT JUST THE BEGINNING?...
The End